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BACKGROUND: We explored the predictive significance of BRCA1, TXR1 and TSP1 expression in non-small-cell lung cancer (NSCLC)
patients treated with docetaxel in association with cisplatin or gemcitabine.
METHODS: To analyse BRCA1, TXR1 and TSP1 mRNA expression from microdissected primary tumours of 131 patients with stage IIIB
(wet) and IV NSCLC, RT–qPCR was used.
RESULTS: The mRNA levels of TXR1/TSP1 were inversely correlated (Spearman’s test:  0.37; P¼0.001). Low TXR1 mRNA levels
were associated with higher response rate (RR; P¼0.018), longer median progression-free survival (PFS; P¼0.029) and median
overall survival (mOS P¼0.003), whereas high TSP1 expression was correlated with higher RR (P¼0.035), longer PFS (Po0.001)
and mOS (Po0.001). Higher BRCA1 mRNA expression was associated with higher RR (P¼0.028) and increased PFS (P¼0.021),
but not mOS (P¼0.4). Multivariate analysis demonstrated that low TXR1/high TSP1 expression was an independent factor
for increased PFS (HR 0.49; 95% CI 0.32–0.76; Po0.001) and mOS (HR 0.37; 95% CI 0.2–0.58; Po0.001), whereas high BRCA1
expression was correlated with increased PFS (HR 0.53; 95% CI 0.37–0.78; P¼0.001).
CONCLUSIONS: These data indicate that TXR1/TSP1 and BRCA1 expression could be used for the prediction of taxanes’ resistance in
the treatment of NSCLC.
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Non-small-cell lung cancer (NSCLC) is the most common visceral
malignancy worldwide for both sexes, accounting for B1.0 million
cancer deaths per year (Jemal et al, 2009). Several drugs are used
for disease control but the combinations of cisplatin with taxanes,
vinorelbine and gemcitabine, have been established as the new
standards of care. Treatment of patients with advanced/metastatic
NSCLC with regimens combining platinum compounds and
taxanes have extended the median survival time to 8–11 months
and the 1-year survival rate to 30–40% (Georgoulias et al, 2001;
Schiller et al, 2002).
There is a growing body of evidence regarding the genetic
factors that could predict response to chemotherapy in NSCLC.
The BRCA1 has emerged as one of the most appealing genetic
markers for the customisation of chemotherapy in NSCLC. It has
multiple roles not only in DNA damage repair but also in cell cycle
regulation, transcriptional control, ubiquitination and apoptosis
(Georgoulias et al, 2001; Mullan et al, 2001; Kennedy et al, 2002),
and it may be a regulator of mitotic spindle assembly as it
colocalises to the microtubules of the mitotic spindle and to the
centromeres (Lotti et al, 2002). Decreased BRCA1 mRNA
expression in a breast cancer cell line led to a greater sensitivity
to cisplatin and etoposide and to a greater resistance to the
microtubule-interfering agents paclitaxel and vincristine (Lafarge
et al, 2001). Reconstitution of wild-type BRCA1 into BRCA1-
negative HCC1937 breast cancer cells resulted in a 20-fold increase
in cisplatin resistance and, in contrast, a 1000- to 10000-fold
increase in sensitivity to paclitaxel and vinorelbine (Quinn et al,
2003). This differential modulating effect of BRCA1 mRNA
expression was also observed in tumour cells isolated from
malignant effusions of NSCLC or gastric cancer patients (Wang
et al, 2008), as well as in patients with ovarian cancer (Quinn et al,
2007), where high BRCA1 mRNA levels correlated negatively
with cisplatin sensitivity and positively with docetaxel sensitivity.
The value of the BRCA1 as a predictive marker for the treatment
customisation in NSCLC has, also, been investigated in
several retrospective studies (Taron et al, 2004; Boukovinas et al,
2008) and in one prospective trial (Boukovinas et al, 2008;
Rosell et al, 2009).
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recently described, suggests that overexpression of a previously
unknown gene, the taxol resistance gene 1 (TXR1) or proline rich
13 (PRR13), prevents apoptosis in a human prostate cancer cell
line (Lih et al, 2006). This effect was mediated by the down-
regulation of the antiangiogenic and proapoptotic glycoprotein
thrombospondin 1 (TSP1). Moreover, the sensitivity of cells in
taxanes was increased by either inactivation of TXR1 using siRNA
or by activating signalling through the integrin-associated protein
(CD47 receptor) (Lih et al, 2006). A retrospective study conducted,
from our group in 96 adenocarcinoma NSCLC patients treated
with docetaxel–gemcitabine, provided evidence for in vivo
relevance of this model. Our results confirmed the in vitro
evidence that overexpression of TXR1 was significantly correlated
with downregulation of TSP1 expression (Po0.0001), and the
expression of both genes was significantly correlated with
treatment outcome (Papadaki et al, 2009).
Based on these data we decided to conduct a retrospective study
in order to investigate the predictive significance of BRCA1 and
TXR1–TSP1 mRNA expression in NSCLC patients treated with
docetaxel-based doublets. The main goal of the study was to
validate, in an independent patients’ cohort, the predictive
significance of TXR1–TSP1 expression in different histologies of
NSCLC and across with chemotherapy regimens combining
docetaxel with platinum compounds (DC) or gemcitabine (DG).
PATIENTS AND METHODS
Patients
A total of 131 consecutive patients with histologically confirmed
stage IIIB (with pleural effusion) and IV NSCLC and available
tumour material for molecular analysis, who were treated with
docetaxel–gemcitabine or docetaxel–cisplatin regimens as first-
line treatment, at the University Hospital of Heraklion (Crete,
Greece) between January 2003 and December 2007 were enroled.
The above group of patients represents an independent patients’
cohort (consecutive patients, not overlapping cases with those of
the previous report) and was used as a confirmatory group
(patients with different histologies and different taxanes regimens)
in order to validate the results reported previously (Boukovinas
et al, 2008; Papadaki et al, 2009). The study has been approved by
the institutional ethics committee and all patients gave their
informed consent for the use of the tissue material for translational
research.
Specimens’ characteristics and assay methods
In order to ensure the validity of the specimen and select the most
appropriate area for microdissection, all paraffin-embedded
tumours were reviewed by two independent pathologists (EL and
ES). Serial sections of 5mm thickness were prepared and then
stained with nuclear Fast Red (Sigma-Aldrich, St Louis, MO, USA).
Cancer cells were procured using an Eppendorf piezoelectric
microdissector (Eppendorf, Hamburg, Germany) (Harsch et al,
2001).
The pellet of microdissected cells was subsequently submitted
for RNA extraction with Trizol LS (Invitrogen, Carlsbad, CA,
USA), and the SuperScript III Reverse Transcriptase (Invitrogen)
was used to prepare cDNA from 50ng of total RNA for each gene
as previously described (Papadaki et al, 2009). The quality of the
extracted RNA was evaluated with amplification of b-actin before
RT–qPCR. Only samples with cycle quantification (Cq) o30 were
considered suitable for further analysis based on the validation
experiments for the performance of the set of primers and probes
(Supplementary Figure 1a and b). The primers and probe sets were
designed using Primer Express 2.0 Software (AB, Foster City, CA,
USA). All primers and probes sequence were previously reported
(Boukovinas et al, 2008; Papadaki et al, 2009). Relative cDNA
quantification for BRCA1, TXR1, TSP1 and b-actin as an internal
reference gene was done using the ABI Prism 7900HT Sequence
Detection System (AB) (Supplementary Figures 2a–d).
Relative gene expression quantification was performed accord-
ing to the comparative Ct method using b-actin as an endogenous
control and commercial RNA controls (mRNA from lung and liver;
Stratagene, La Jolla, CA, USA) as calibrators. In addition, RNA
extracted from FFPE lung tissue of a normal individual (who was
operated after an accident) was used as internal standard during
the whole experiment. Final results were determined as follows:
2
 (DCt sample DCt calibrator), where DCT values of the calibrator
and sample were determined by subtracting the CT value of the
target gene from the value of the reference gene. In all experiments,
only triplicates with s.d. of the Ct value o0.25 were accepted,
according to the manufacturer suggestions (AB 7900 and SDS 2.3
User guide; AB). In addition, genomic DNA contamination of each
sample has been excluded by non-reverse transcription of RNA.
Study design and statistics
This study was a retrospective analysis aiming to explore the
predictive significance of BRCA1, TXR1 and TSP1 mRNA
expression in patients with NSCLC treated with front-line DG or
DC regimen, in an independent, confirmatory group of patients.
All appropriate specimens of the primary tumour with 4100 cells
per section were included in the analysis. Objective responses were
recorded according to the RECIST criteria (Therasse et al, 2000).
All efficacy results were assessed on an intention-to-treat basis.
Median progression-free survival (PFS) was measured from the
date of first-line therapy initiation to the first radiographic
documentation of disease progression or death and median overall
survival (mOS) was calculated from the date of diagnosis of
metastatic disease to death from any cause. Quantitative PCR
analyses yielded values that were expressed as ratios between two
absolute measurements (gene of interest: internal reference gene).
Cutoff points were calculated according to the median value for the
mRNA expression of each gene (Rosell et al, 2003; Taron et al,
2004). Samples with mRNA expression above or equal to the
median were considered as samples with high expression, whereas
those with value below the median as samples with low expression.
All laboratory analyses were performed blinded to the clinical data.
Associations between treatment response and mRNA expression
or baseline characteristics were assessed using Fisher’s exact test
for dichotomous variables or logistic regression for continuous
variables. Kaplan–Meier curves were used to describe the
proportion of subjects who remained free of events over the
follow-up period. Associations between prognostic factors and PFS
or OS were examined using Cox proportional hazards regression
models; we report hazard ratio (HR) estimates and their 95%
confidence intervals (CIs).
Cox regression models with interaction terms were used to
assess whether mRNA expression effects varied across treatment
subgroups. For each gene mRNA expression, two hypotheses were
tested: (1) whether effect on first-line PFS and mOS varied
according to regimen (DG or DC); and (2) whether the effect on
first-line PFS and mOS varied according to tumour histology
(squamous or non-squamous). All reported P-values were two
sided and not adjusted for multiple testing.
RESULTS
Patients’ characteristics
Clinical data and representative samples from the primary
tumours were collected from 131 consecutive patients treated with
Q1
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tion of both genes was achieved in all 131 specimens. Patient
characteristics were all typical for NSCLC and are summarised in
Table 1a.
In an intention-to-treat analysis, complete response (CR) was
observed in 2 (2%) and partial response (PR) in 38 (28%) patients
(overall response rate (RR) 30%; 95% CI 24.3–39.2%). After a
median follow-up period of 9.7 months (range 1.3–84.5), the
median PFS was 4.2 months (95% CI 2.7–5.7) and the median OS
was 11.1 months (95% CI 9.7–14.6).
Genes’ mRNA expression levels and response to treatment
The median mRNA expression levels were 4.28 (range 0.86–42.45)
for BRCA1, 1.21 (range 0.02–7.8) for TXR1 and 0.24 (range 0.02–1.87)
for TSP1. There was no correlation between age, gender,
performance status or stage of disease and BRCA1, TXR1 or
TSP1 mRNA levels (all P-values 40.05). In comparison with
non-squamous tumours (median 3.62; P¼0.001), BRCA1 was
significantly higher in squamous tumours (median 8.1),whereas
TXR1 and TSP1 expression was almost identical between the two
histology groups (Table 1b) and in the same range with those
reported for the previous patients’ cohort (Papadaki et al, 2009).
Furthermore, we observed the same inverse correlation between
TXR1 and TSP1 mRNA expression (Spearman’s test  0.37;
P¼0.001). For the BRCA1, as the expression values were
significantly higher in squamous cell carcinomas in comparison
with the adenocarcinomas (P¼0.001), the cutoff values were
calculated according to median expression levels in each group of
squamous and non-squamous histology. Using these cutoff values,
low (below the median) tumoural BRCA1 expression was observed
in 28 (50%) squamous and 38 (50%) non-squamous specimens,
whereas high (above or equal to the median) in 28 (50%) and
37 (50%) patients with squamous and non-squamous tumours,
respectively.
BRCA1, TXR1, and TSP1 expression levels and
treatment outcome
Table 2 summarises the treatment outcomes according to BRCA1,
TXR1 and TSP1 mRNA expression. Patients with high BRCA1
mRNA expression had increased PFS (6.0 vs 3.0 months; P¼0.021;
Figure 1A) and RR (42 vs 20%; P¼0.028) in comparison with those
with low BRCA1 mRNA levels. Conversely, there was no difference
in terms of OS according to the BRCA1 mRNA expression
(10.5 vs 11.2 months; P¼0.4; Figure 2A). Patients with low TXR1
expression experienced a longer PFS (5.5 vs 3.0 months; P¼0.029;
Figure 1B), OS (19.1 vs 10.0 months; P¼0.003; Figure 2B) and RR
(45 vs 18%, P¼0.018) when compared with patients whose
tumours had high TXR1 mRNA expression. In addition, patients
with high TSP1 expression presented longer PFS (6.1 vs 2.6
months; Po0.001; Figure 1C), OS (25.1 vs 8.4 months; Po0.001;
Figure 2C) and RR (41 vs 22%; P¼0.035) when compared with
patients with low TSP1 mRNA expression.
Table 1a Patients’ characteristics
Patients treated with DG or DC
Number %
Gender
Male 106 88
Female 25 12
Age (years)
Median 60
Range 37–78
Performance status (ECOG)
06 7 5 1
15 2 4 0
21 2 9
Stage
IIIB (wet) 35 27
IV 96 73
Histology
Adenocarcinoma 68 52
Squamous 56 43
Other 7 5
Regimen
Docetaxel cisplatin 64 49
Docetaxel Gemcitabine 67 51
Response rate (CR+PR) 40 30
PFS (months, 95% CI) 4.2 (2.7–5.7)
Median OS (months, 95% CI) 11.1 (9.7–14.6)
Abbreviations: CR¼complete response; PR¼partial response; PFS¼progression-
free survival; OS¼overall survival; CI¼confidence interval; ECOG¼Eastern
Cooperative Oncology Group; DG¼docetaxel and gemcitabine; DC¼docetaxel
and cisplatin.
Table 1b BRCA1, TXR1 and TSP1 tumoural mRNA expression
All patients Squamous Non-squamous P-value
a
No. of patients (%) 131 (100) 56 (43) 75 (52)
BRCA1
Expression value, median (range) 4.28 (0.86–42.45) 8.1 (1.73–42.45) 3.62 (0.72–39.31) 0.001
High expression 65 (50) 28 (50) 37 (50)
Low expression 66 (50) 28 (50) 38 (50)
TXR1
Expression value, median (range) 1.21 (0.02–7.8) 1.19 (0.02–6.7) 1.21 (0.12–7.8) 0.92
High expression 65 (50) 28(50) 36 (50)
Low expression 66 (50) 28(50) 38 (50)
TSP1
Expression value, median (range) 0.24 (0.02–1.87) 0.23 (0.02–1.54) 0.24 (0.02–1.87) 1.0
High expression 65 (50) 28 (50) 36 (50)
Low expression 66 (50) 28 (50) 38 (50)
Abbreviations: BRCA1¼breast cancer 1 gene; TSP1¼thrombospondin 1; TXR1¼taxol resistance gene 1.
aMann–Whitney U-test, P-value.
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according to histological subtype and first-line
regimen used
The correlation between high BRCA1 mRNA expression and
increased PFS was significant for both patients with squamous and
non-squamous histology (interaction test P¼0.61), whereas no
significant correlation with mOS was found for either histological
subtype (interaction test P¼0.97; Table 3A). Similarly, the
correlation between high TXR1 mRNA expression and decreased
PFS (interaction test P¼0.21) and mOS (interaction test P¼0.19)
was comparable (Table 3A). Finally, high TSP1 mRNA expression
retained its predictive significance for increased PFS (interaction
test P¼0.34) and mOS (interaction test P¼1.0) among patients
with squamous and non-squamous histology (Table 3A).
Likewise, the correlation between high TXR1 mRNA expression
and decreased PFS (interaction test P¼0.56) and mOS (interaction
test P¼0.38) was observed for patients receiving either DG or DC
regimens (Table 3B). Moreover, PFS (interaction test P¼0.48) and
mOS (interaction test P¼0.93) were significantly correlated with
TSP1 mRNA expression in either DG or DC treatment regimens
(Table 3B). In contrast, high BRCA1 mRNA expression was
Table 2 Tumoural expression of BRCA1, TXR 1 and TSP1 mRNA and treatment efficacy
PFS (months) OS (months) RR, N (%)
Genes No. of patients Median (95% CI) P-value
a Median (95% CI) P-value
a CR+PR (%) SD+PD(%) P-value
BRCA1 low 66 (50) 3.0 (2.3–3.7) 0.021 10.5 (6.2–14.8) 0.4 20 80 0.028
BRCA1 high 65 (50) 6.0 (3.5–8.5) 11.2 (7.2–15.3) 42 58
TXR1 low 66 (50) 5.5 (2.1–8.9) 0.029 19.1 (10.4–27.9) 0.003 45 55 0.018
TXR1 high 65 (50) 3.0 (1.8–4.0) 10.0 (7.4–12.7) 18 82
TSP1 low 66 (50) 2.6 (2.0–3.3) o0.001 8.4 (5.2–11.6) o0.001 22 78 0.035
TSP1 high 65 (50) 6.1 (4.4–7.7) 25.1 (11.1–39.2) 41 59
Abbreviations: BRCA1¼breast cancer 1 gene;C R ¼complete response; RR¼response rate; PR¼partial response; PFS¼progression-free survival; OS¼overall survival;
CI¼confidence interval; SD¼stable disease; PD¼progressive disease; TSP1¼thrombospondin 1; TXR1¼taxol resistance gene 1.
aLog-rank P-value.
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Figure 1 Progression-free survival (PFS) according to BRCA1 (A), TXR1 (B) and TSP1 (C) mRNA expression.
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with DG regimen but not in those treated with DC (interaction test
P¼0.006); on the contrary, no such significant association with
mOS was observed in either treatment group (interaction test
P¼0.61; Table 3B). In addition, 42 (63%) patients treated with
first-line DG received second-line treatment with a cisplatin-based
combination; BRCA1 mRNA expression was significantly corre-
lated with PFS (5.7 vs 2.2 months for patients with low and high
mRNA expression; P¼0.01) in this subgroup of patients.
Univariate and multivariate analyses
Univariate analysis demonstrated that high TXR1 (P¼0.002)
mRNA expression and stage IV (P¼0.02) as diagnosis factors were
significantly associated with decreased PFS, whereas high TSP1
(Po0.001) and BRCA1 (P¼0.02) mRNA expression were asso-
ciated with increased PFS. In addition, performance status of 2
(P¼0.04), high TXR1 (P¼0.003) and low TSP1 (Po0.001) mRNA
expression were significantly associated with decreased OS
(Table 4A). Cox proportional hazard analysis revealed that the
combined expression of TXR1 and TSP1 (low TXR1/high TSP1
expression) (HR 0.49; 95% CI 0.32–0.76; Po0.001) and BRCA1
(HR 0.53; 95% CI 0.37–0.78; P¼0.001) expression emerged as
independent factors associated with increased PFS (Table 4B).
Moreover, performance status (2 vs 0–1; HR 1.92; 95% CI 1.02–
3.60; P¼0.04) and TXR1 and TSP1 (low TXR1/high TSP1
expression; HR 0.37; 95% CI 0.23–0.58; Po0.001) were indepen-
dent prognostic factors for OS (Table 4b).
DISCUSSION
Downregulation of TSP1 through TXR1 overexpression has
been proposed as a novel mechanism that modulates the
cellular cytotoxicity of taxanes in vitro (Lih et al, 2006);
indeed, in a previous report we have confirmed the clinical
relevance of this mechanism in a group of patients with
lung adenocarcinomas treated with a chemotherapy regimen
combining docetaxel and gemcitabine (Papadaki et al, 2009).
In this we evaluated the predictive significance of TXR1
overexpression/TSP1 downregulation, together with BRCA1 mRNA
expression, in samples from patients with all histologies of NSCLC
treated with either docetaxel/gemcitabine or docetaxel/cisplatin
combinations.
We observed that the median expression values of TXR1 and
TSP1 were almost identical between squamous and non-squamous
carcinomas (P-value¼0.92 and 1.0, respectively) and we
confirmed that overexpression of TXR1 was significantly
correlated with downregulation of TSP1 expression (P¼0.001).
In addition, multivariate analysis revealed that the favourable
genotype (low TXR1/high TSP1 expression) was an independent
prognostic factor for increased PFS and survival, and was
associated with a 51 and 63% reduction of the risk for progression
or death, respectively. It is interesting to note that the predictive
value of TXR1 and TSP1 expression for PFS and median OS was
retained irrespectively of the tumour histology. All these results are
in agreement with the published in vitro and in vivo data regarding
the role of TXR1–TSP1 expression in taxanes’ resistance (Lih et al,
2006; Papadaki et al, 2009).
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Figure 2 Median OS according to BRCA1 (A), TXR1 (B) and TSP1 (C) mRNA expression.
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different in squamous and non-squamous tumours (P¼0.001),
as has been previously reported (Rosell et al, 2007).
Overexpression of BRCA1 was significantly correlated with higher
RR and PFS but not with mOS. The predictive value of BRCA1 in
PFS remained significant in both squamous and non-squamous
groups (interaction test P¼0.61). On the contrary, overexpression
of BRCA1 was significantly correlated with increased PFS in
patients treated with DG but not in those treated with DC regimen
(interaction test P¼0.006). These results are in agreement with the
current evidence for the differential predictive value of BRCA1,a s
low BRCA1 expression confers increased sensitivity to cisplatin
(Husain et al, 1998; Lafarge et al, 2001; Quinn et al, 2003, 2007)
and resistance to antimicrotubule drugs such as docetaxel (Quinn
Table 3 Correlation of tumoural expression of BRCA1, TXR1 and TSP1 mRNA and treatment efficacy (a) in different histological subtypes and (b) across
taxane-based regimens
PFS (months) OS (months)
Genes
No. of
patients
Median
(95% CI)
Log-rank
P-value
Interaction
P-value
Median
(95% CI)
Log-rank
P -value
Interaction
P-value
(A)
Histology
Squamous BRCA1 low 28 (50) 4.0 (1.5–7.6) 0.047 0.61 11.3 (5.5–17.2) 0.99 0.97
BRCA1 high 28 (50) 7.4 (4.7–10.1) 9.8 (4.8–17.0)
Non-squamous BRCA1 low 38 (51) 3.8 (2.1–5.5) 0.041 11.2 (8.3–16.1) 0.91
BRCA1 high 37 (49) 7.2 (4.3–9.1) 11.1 (8.8–15.6)
Squamous TXR1 low 28 (50) 7.1 (3.4–9.7) 0.038 0.21 16.4 (10.9–19.5) 0.022 0.19
TXR1 high 28 (50) 4.2 (1.6–7.8) 8.3 (2.6–12.1)
Non-squamous TXR1 low 38 (51) 6.4 (3.8–9.6) 0.027 23.2 (10.2–38.1) 0.007
TXR1 high 37 (49) 3.3 (1.9–3.6) 8.7 (5.2–12.3)
Squamous TSP1 low 28 (50) 3.6 (1.4–7.3) 0.019 0.34 9.0 (4.6–13.5) 0.001 1.0
TSP1 high 28 (50) 6.1 (3.8–10.6) 25.2 (10.2–47.8)
Non-squamous TSP1 low 38 (51) 2.3 (2.1–2.5) 0.001 7.9 (3.0–12.7) 0.001
TSP1 high 37 (49) 6.3 (3.2–10.3) 23.2 (10.4–41.8)
(B)
Regimen
Docetaxel–gemcitabine BRCA1 low 34 (51) 3.5 (2.1–4.8) 0.013 0.006 11.1 (6.8–15.5) 0.458 0.613
BRCA1 high 33 (49) 6.2 (4.1–8.5) 10.2 (3.9–17.6)
Docitaxel–cisplatin BRCA1 low 32 (50) 6.8 (3.7–10.0) 0.874 11.2 (8.3–16.1) 0.912
BRCA1 high 32 (50) 6.1 (4.5–7.7) 11.1 (8.8–15.6)
Docetaxel–gemcitabine TXR1 low 34 (51) 7.2 (4.9–9.7) 0.024 0.56 15.8 (8.2–25.9) 0.013 0.387
TXR1 high 33 (49) 3.3 (2.1–4.4) 8.5 (4.1–12.8)
Docitaxel–cisplatin TXR1 low 32 (50) 7.4 (4.2–10.3) 0.032 23.2 (10.2–38.1) 0.007
TXR1 high 32 (50) 3.7 (1.4–5.2) 8.7 (3.9–12.3)
Docetaxel–gemcitabine TSP1 low 34 (51) 3.4 (2.1–4.8) 0.007 0.48 7.5 (5.4–11.4) 0.006 0.931
TSP1 high 33 (49) 6.8(4.6–9.7) 26.7 (10.9–43.6)
Docitaxel–cisplatin TSP1 low 32 (50) 4.4 (1.6–8.1) 0.002 9.1 (5.4–12.7) 0.002
TSP1 high 32 (50) 7.6 (4.3–12.8) 36.4 (16.7–50.1)
Abbreviations: BRCA1¼breast cancer 1 gene;P F S¼progression-free survival; OS¼overall survival; CI¼confidence interval; TSP1¼thrombospondin 1; TXR1¼taxol resistance gene 1.
Table 4A Univariate analysis for PFS and OS
HR 95% CI P-value
PFS
BRCA1 expression (high vs low) 0.65 0.45–0.94 0.02
TXR1 expression (high vs low) 1.61 1.17–2.43 0.002
TSP1 expression (high vs low) 0.49 0.34–0.72 o0.001
TXR1–TSP1 expression
(TXR1 low/TSP1 high vs others)
0.60 0.39–0.90 0.01
PS (2 vs 0–1) 1.66 0.89–3.10 0.13
Age (470 years vs p70 years) 1.17 0.77–1.84 0.48
Gender (male vs female) 1.30 0.72–2.33 0.38
Stage (IV vs IIIb) 1.90 1.15–2.58 0.02
OS
BRCA1 expression (high vs low) 1.02 0.69–1.50 0.93
TXR1 expression (high vs low) 1.83 1.23–2.73 0.003
TSP1 expression (high vs low) 0.34 0.22–0.53 o0.001
TXR1–TSP1 expression
(TXR1 low/TSP1 high vs others)
0.38 0.24–0.62 o0.001
PS (2 vs 0–1) 1.92 1.02–3.58 0.04
Age (470 years vs p70 years) 1.27 0.79–2.04 0.33
Gender (male vs female) 1.57 0.77–3.59 0.18
Stage (IV vs IIIb) 1.73 1.03–2.24 0.04
Abbreviations: BRCA1¼breast cancer 1 gene; PFS¼progression-free survival;
PS¼performance status; OS¼overall survival; CI¼confidence interval; HR¼hazard
ratio; TSP1¼thrombospondin 1; TXR1¼taxol resistance gene 1. Values shown in bold
are statistically significant.
Table 4B Multivariate analysis for time to tumour progression and OS
HR 95% CI P-value
PFS
Stage (IV vs IIIb) 1.41 0.94–1.66 0.09
BRCA1 expression (high vs low) 0.53 0.37–0.78 0.001
TXR1–TSP1 expression
(TXR1 low/TSP1 high vs others)
0.49 0.32–0.76 o0.001
OS
Stage (IV vs IIIb) 1.42 0.92–2.74 0.2
TXR1–TSP1 expression
(TXR1 low/TSP1 high vs others)
0.37 0.23–0.58 o0.001
PS (0–1 vs 2) 1.92 1.02–3.60 0.04
Abbreviations: BRCA1¼breast cancer 1 gene; PFS¼progression-free survival;
PS¼performance status; OS¼overall survival; CI¼confidence interval; HR¼hazard
ratio; TSP1¼thrombospondin 1; TXR1¼taxol resistance gene 1. Values shown in bold
are statistically significant.
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set al, 2007), whereas high BRCA1 expression leads to resistance to
cisplatin (Husain et al, 1998; Lafarge et al, 2001; Taron et al, 2004;
Rosell et al, 2009) and sensitivity to docetaxel (Quinn et al, 2007;
Boukovinas et al, 2008; Rosell et al, 2009). In addition, BRCA1
overexpression is significantly correlated with those of ERCC1 and
RRM1 in several studies (Rosell et al, 2007; Boukovinas et al, 2008;
Wang et al, 2008; Bartolucci et al, 2009), providing another
explanation for the lack of association of BRCA1 with OS.
High BRCA1 mRNA expression has been associated with
increased risk of relapse in patients with early (stage IB–IIB)
NSCLC (Bartolucci et al, 2009), whereas BRCA1 haplotype could
predict the outcome of NSCLC cancer patients treated with
platinum-based chemotherapy, especially of those with squamous
cell histology (Kim et al, 2008); these findings could explain the
lack of significant association between BRCA1 expression and
efficacy of the DC regimen observed in this study. Similarly,
BRCA1 protein expression was not a predictive factor for response
to treatment in patient with operable NSCLC treated with DC in
the neoadjuvant setting (Kang et al, 2010). Finally, the poor
correlation of BRCA1 with OS, especially in patients treated with
DG, could be partially explained by the fact that second-line
cisplatin chemotherapy is more effective in patients with low
BRCA1 expression as has been previously reported (Boukovinas
et al, 2008), as was the case in the present study.
The effect of TXR1–TSP1 mRNA expression on taxanes’
cytotoxicity is independent of MDR phenotype (the ability of
tumour cells to efflux taxanes through the upregulation of the
ATP-dependent cell membrane glycoproteins) (Gottesman and
Ling, 2006), as the overexpression of TXR1 did not affect the
cellular accumulation of [
3H]-labelled-paclitaxel in the resistant
cells and did not reduce the sensitivity to other agents that are also
expelled from tumour cells by the MDR (Lih et al, 2006). Also, it
seems to be independent from tubulin formation (the mutations of
the b-tubulin gene that may interfere with the taxane-binding sites
to microtubules) (Giannakakou et al, 1997, 2000a,b; Kavallaris
et al, 1997), as quantitative biochemical analysis of cell lines
resistant to taxanes has shown the same tubulin dynamics as that
of the parental (sensitive) cells and no increase in microtubules’
isoforms that are commonly upregulated in tubulin-related
resistance to taxanes (Gottesman and Ling, 2006; Lih et al, 2006).
Owing to the lack of a non-taxane-treated control group in our
study, we cannot confirm that the effect of TSP1 expression was
taxane specific and not a simple predictive marker for response
to chemotherapy. In many human cancers, TSP1 expression is
inversely correlated with progression, and it was also found to be
an independent prognostic indicator (Neal et al, 2006; Guerrero
et al, 2008). However, using cDNA microarrays, it has been
previously shown that the induction of TSP1 in docetaxel-treated
head and neck squamous cell carcinoma cell lines increased
cytotoxicity (Yoo et al, 2002). The TSP1 is considered a
proapoptotic protein through the activation of CD47 cell surface
receptor (Lih et al, 2006), which has previously been shown to
result in not only caspase-independent (Mateo et al, 1999) but also
caspase-dependent apoptosis (Manna et al, 2005). In addition,
TSP1 is a strong inhibitor of angiogenesis and decreased levels of
circulating TSP1 in certain inbred mouse strains are correlated
with increased circulating endothelial precursors and susceptibility
to cancers (Shaked et al, 2005). In NSCLC, reduced protein
expression of TSP1 has been associated with increased micro-
vessels count and unfavourable prognosis (Yamaguchi et al, 2002).
On the other hand, overexpression of TSP1 has also been
associated with aggressiveness and increased angiogenesis in lung
cancer (Ioachim et al, 2006).
Despite the fact that the results of this study should be
interpreted with caution because of the retrospective nature of
the study, it seems that the TXR1–TSP1 mRNA expression could
be used as predictive markers for patients with NSCLC treated with
docetaxel-based chemotherapy. The next step should be the
evaluation of the significance of TXR1/TSP1 expression in taxanes’
chemosensitivity in other tumour types such as breast and ovarian
cancer, where taxanes are commonly used in the daily clinical
practice. If this will be the case, the clinical relevance of the TXR1/
TSP1 expression should be further validated in prospective
adequately designed clinical trials.
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